Spots Global Cancer Trial Database for A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
Official Title: Phase 1/2 Open-label Study of BMS-986466 in Combination With Adagrasib With or Without Cetuximab in Participants With KRAS G12C-mutant Advanced Solid Tumors
Study ID: NCT06024174
Conditions
Study Description
Brief Summary: The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC), pancreatic duct adenocarcinoma (PDAC), biliary tract cancer (BTC), or colorectal cancer (CRC).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Valkyrie Clinical Trials, Los Angeles, California, United States
University Cancer Blood Ctr, Athens, Georgia, United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Atlantic Health System Morristown Medical Center, Morristown, New Jersey, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
Local Institution - 0075, Ciudad Aut贸noma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0084, ABB, Ciudad Aut贸noma De Buenos Aires, Argentina
Local Institution - 0076, Buenos Aires, , Argentina
Local Institution - 0086, C贸rdoba, , Argentina
Local Institution - 0077, C贸rdoba, , Argentina
Local Institution - 0053, Westmead, New South Wales, Australia
Local Institution - 0078, Elizabeth Vale, South Australia, Australia
Local Institution - 0049, Brussels, Bruxelles-Capitale, R茅gion De, Belgium
Local Institution - 0048, Gent, Oost-Vlaanderen, Belgium
Local Institution - 0050, Leuven, Vlaams-Brabant, Belgium
CHU de Bordeaux Hop St ANDRE, Bordeaux, Aquitaine, France
Assistance Publique H么pitaux de Marseille - H么pital de la Timone, Marseille, Bouches-du-Rh么ne, France
Gustave Roussy, Villejuif, Val-de-Marne, France
Centre Hospitalier Universitaire de Poitiers, Poitiers, Vienne, France
Hopital Claude Huriez - CHU de Lille, Lille, , France
Local Institution - 0082, Petah Tikva, HaMerkaz, Israel
Local Institution - 0081, Tel Aviv, Tell Ab墨b, Israel
Local Institution - 0043, Ravenna, Emilia-Romagna, Italy
Local Institution - 0042, Milan, Milano, Italy
Local Institution - 0046, Rome, Roma, Italy
Local Institution - 0065, Badalona, Barcelona [Barcelona], Spain
Local Institution - 0069, Barcelona, Barcelona [Barcelona], Spain
Local Institution - 0066, Madrid, Madrid, Comunidad De, Spain
Local Institution - 0070, Madrid, Madrid, Comunidad De, Spain
Local Institution - 0067, Madrid, Madrid, Comunidad De, Spain
Local Institution - 0068, Sevilla, , Spain
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
